Company: BLTE
Filing Date: 2025-10-22
Form Type: F-3ASR
Source: 0001104659-25-101403
Chunk: 65

Company: BELITE BIO, INC
Filing Date: 2025-10-22
Form: F-3ASR
Chunk 65
---
 list of Selling Shareholders to include the pledgee, transferee or other successors in interest as Selling Shareholders under this prospectus. The Selling Shareholders also may transfer the ordinary shares (or ADSs represented thereby) in other circumstances, in which case the transferees, pledgees or other successors in interest will be the Selling Shareholders for purposes of this prospectus.

In connection with the sale of our ordinary shares (or ADSs represented thereby) or interests therein, the Selling Shareholders may enter into hedging transactions with broker-dealers or other financial institutions, which may in turn engage in short sales of the ordinary shares (or ADSs represented thereby) in the course of hedging the positions they assume. The Selling Shareholders may also sell our ordinary shares (or ADSs represented thereby) short and deliver these securities to close out their short positions, or loan or pledge the ordinary shares (or ADSs represented thereby) to broker-dealers that in turn may sell these securities. The Selling Shareholders may also enter into option or other transactions with broker-dealers or other financial institutions or the creation of one or more derivative securities which require the delivery to such broker-dealer or other financial institution of securities offered by this prospectus, which securities such broker-dealer or other financial institution may resell pursuant to this prospectus (as supplemented or amended to reflect such transaction).

<div align='center'>44</div>

TABLE OF CONTENTS

The aggregate proceeds to the Selling Shareholders from the sale of the ordinary shares (or ADSs represented thereby) offered by them will be the purchase price of the ordinary shares (or ADSs represented thereby) less discounts or commissions, if any. Each of the Selling Shareholders reserves the right to accept and, together with their agents from time to time, to reject, in whole or in part, any proposed purchase of ordinary shares (or ADSs represented thereby) to be made directly or through agents. We will not receive any of the proceeds from this resale offering. Upon any exercise of the warrants by payment of cash, however, we will receive the exercise price of the warrants.

The Selling Shareholders also may resell all or a portion of the ordinary shares (or ADSs represented thereby) in open market transactions in reliance upon Rule 144 under the Securities Act, provided that they meet the criteria and conform to the requirements of that rule, or another available exemption from the registration requirements under the Securities Act.

The Selling Shareholders and any underwriters, broker-dealers or agents that participate in